A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease.
10.3779/j.issn.1009-3419.2020.102.01
- Author:
Yanning WANG
1
;
Yujie ZHOU
1
;
Liyun MIAO
1
Author Information
1. Department of Respiration, Nanjing Drum Tower Hospital, Nanjing 210008, China.
- Publication Type:Journal Article
- Keywords:
Drug treatment;
Interstitial pneumonia;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2020;23(4):286-293
- CountryChina
- Language:Chinese
-
Abstract:
Interstitial lung disease (ILD) is a risk factor for lung cancer. Patients with lung cancer associated with ILD (LC-ILD) often appear clinically. During the treatment of LC-ILD, there is a risk of causing acute exacerbation or even death in the treatment of lung cancer. At the same time, combining ILD has become the exclusion criteria for prospective clinical trials of most lung cancers. Therefore, when lung cancer is combined with ILD, it often becomes a difficult point for the treatment of lung cancer. Because LC-ILD patients have a certain proportion in the clinic, it is necessary to explore the best treatment options. Here we review the results of existing clinical studies for reference.
